125561 Apr 2026

Under number 125561 , written evidence was submitted by Mrs. C. Roche to the UK Parliament regarding the impact of screen time and "digital drugs" on children’s brains and ADHD .

A paper titled " Optimal nonparametric inference via deep neural network " is indexed under this number (Article 125561) in the Journal of Mathematical Analysis and Applications . 125561

In the medical field, is the Biologics License Application (BLA) number for Kanuma (sebelipase alfa) . Under number 125561 , written evidence was submitted by Mrs

The identifier appears across several distinct contexts, most notably as an FDA application number for the drug Kanuma and as an article identifier for a research paper on optimal nonparametric inference using deep neural networks. Pharmaceutical: FDA BLA 125561 A paper titled " Optimal nonparametric inference via

Another technical reference exists for "Deep fuzzy C-means clustering in a federated heterogeneous scenario," which uses a similar DOI sequence (10.1109/JAS.2025. 125561 ). Public Records & Evidence

The application was submitted by Alexion Pharmaceuticals and received FDA approval in September 2015 . Academic & Technical Research

The number also serves as a specific article identifier (often part of a DOI or page reference) in various scientific journals: